Development of an efficient neutralization assay for Coxsackievirus A10
- 68 Downloads
Coxsackievirus A10 (CVA10) recently has become one of the major pathogens of hand, foot, and mouth disease (HFMD) in children worldwide, but no cure or vaccine against CVA10 is available yet. Serological evaluation of herd immunity to CVA10 will promote the development of vaccine. The traditional neutralization assay based on inhibition of cytopathic effect (Nt-CPE) is a common method for measuring neutralizing antibody titer against CVA10, which is time-consuming and labor-intensive. In this study, an efficient neutralization test based on a monoclonal antibody (mAb) 3D1 against CVA10, called Elispot-based neutralization test (Nt-Elispot), was developed. In the Nt-Elispot, the mAb 3D1 labeled with horseradish peroxidase (HRP) was used to detect the CVA10-infected RD cells at a 1:4000 dilution and the optimal infectious dose of CVA10 was set at 105 TCID50/well when combined with a fixed incubation time of 14 h. Compared with the Nt-CPE, the Nt-Elispot method effectively shortened the detection period and presented a good correlativity with it. Using the Nt-Elispot, a total of 123 sera from healthy children were tested for neutralizing antibody against CVA10, demonstrating that the overall seroprevalence was 49.3% (54/123) and the geometric mean titer (GMT) had been calculated as 574.2. Furthermore, 2 anti-CVA10 neutralizing mAbs were obtained by screening via the Nt-Elispot. Overall, the established Nt-Elispot could be used as an efficient and high-throughput method for evaluating immunity to CVA10 and screening the neutralizing antibodies.
KeywordsCoxsackievirus A10 Neutralizing antibody Elispot Serological epidemiology
We thank the editors at NPG Language Editing who provided editing assistance to the authors during the preparation of this manuscript.
This work was supported by a grant from the National Science and Technology Major Project of Infectious Diseases (No.2017ZX10304402), the National Natural Science Foundation of China (Nos. 81801646, 31670933, and 81701999), and the National Science and Technology Major Projects for Major New Drugs Innovation and Development (No. 2018ZX09711003-005-003). The sponsors had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Compliance with ethical standards
Conflict of interest
All authors declare that they have no conflict of interest.
All procedures performed in studies involving animal experiments were approved by Xiamen University Laboratory Animal Center (XMULAC) and conducted in accordance with animal ethics guidelines and approved protocols. The Animal Ethics Committee approval number was XMULAC20160049. All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committees of the Xiamen City Center for Disease Control and Prevention and the Xiamen University.
Informed consent was obtained from all individual participants included in the study.
- Davia JL, Bel PH, Ninet VZ, Bracho MA, Gonzalez-Candelas F, Salazar A, Gobernado M, Bosch IF (2011) Onychomadesis outbreak in Valencia, Spain associated with hand, foot, and mouth disease caused by enteroviruses. Pediatr Dermatol 28(1):1–5. https://doi.org/10.1111/j.1525-1470.2010.01161.x CrossRefGoogle Scholar
- Jin P, Li J, Zhang X, Meng F, Zhou Y, Yao X, Gan Z, Zhu F (2016) Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6-35 months. Hum Vaccin Immunother 12(4):916–921. https://doi.org/10.1080/21645515.2015.1118595 CrossRefGoogle Scholar
- Li S, Yang L, Hou W, Zhao H, Wan J, Chen M, HE S, Cheng T, Xia N (2016) Development and application of a novel neutralization test for echovirus 25. Lett Microbiol 1009–0002Google Scholar
- Lim H, In HJ, Lee JA, Sik Yoo J, Lee SW, Chung GT, Choi YK, Chung JK, Cho SJ, Lee JW (2018) The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease. Vaccine 36(24):3445–3452. https://doi.org/10.1016/j.vaccine.2018.05.005 CrossRefGoogle Scholar
- Liu CC, Guo MS, Lin FH, Hsiao KN, Chang KH, Chou AH, Wang YC, Chen YC, Yang CS, Chong PC (2011) Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS One 6(5):e20005. https://doi.org/10.1371/journal.pone.0020005 CrossRefGoogle Scholar
- Luo Y, Xiong D, Li H, Qiu S, Lin C, Chen Q, Huang C, Yuan Q, Zhang J, Xia N (2016) Development of an HSV-1 neutralization test with a glycoprotein D specific antibody for measurement of neutralizing antibody titer in human sera. Virol J 13:44. https://doi.org/10.1186/s12985-016-0508-4 CrossRefGoogle Scholar
- Mao Q, Cheng T, Zhu F, Li J, Wang Y, Li Y, Gao F, Yang L, Yao X, Shao J, Xia N, Liang Z, Wang J (2013) The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy chinese infants and children. PLoS One 8(11):e79599. https://doi.org/10.1371/journal.pone.0079599 CrossRefGoogle Scholar
- Mirand A, Henquell C, Archimbaud C, Ughetto S, Antona D, Bailly JL, Peigue-Lafeuille H (2012) Outbreak of hand, foot and mouth disease/herpangina associated with coxsackievirus A6 and A10 infections in 2010, France: a large citywide, prospective observational study. Clin Microbiol Infect 18(5):E110–E118. https://doi.org/10.1111/j.1469-0691.2012.03789.x CrossRefGoogle Scholar
- Wan J, Wang W, Hou W, Li S, Zhao H, Zheng Q, He S, Cheng T, Xia N (2017) Development and application of a novel neutralization test for enterovirus D68. Chin J VirolGoogle Scholar
- WHO (1997) Manual for the virological investigation of polio Global programme for vaccines and immunization, expanded programme on immunization. World Health Organization, GenevaGoogle Scholar
- Xing W, Liao Q, Viboud C, Zhang J, Sun J, Wu JT, Chang Z, Liu F, Fang VJ, Zheng Y, Cowling BJ, Varma JK, Farrar JJ, Leung GM, Yu H (2014) Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect Dis 14(4):308–318. https://doi.org/10.1016/S1473-3099(13)70342-6 CrossRefGoogle Scholar
- Xu L, Zheng Q, Li S, He M, Wu Y, Li Y, Zhu R, Yu H, Hong Q, Jiang J, Li Z, Li S, Zhao H, Yang L, Hou W, Wang W, Ye X, Zhang J, Baker TS, Cheng T, Zhou ZH, Yan X, Xia N (2017) Atomic structures of Coxsackievirus A6 and its complex with a neutralizing antibody. Nat Commun 8(1):505. https://doi.org/10.1038/s41467-017-00477-9 CrossRefGoogle Scholar
- Yang L, He D, Tang M, Li Z, Liu C, Xu L, Chen Y, Du H, Zhao Q, Zhang J, Cheng T, Xia N (2014) Development of an enzyme-linked immunosorbent spot assay to measure serum-neutralizing antibodies against coxsackievirus B3. Clin Vaccine Immunol 21(3):312–320. https://doi.org/10.1128/CVI.00359-13 CrossRefGoogle Scholar
- Zhang D, Chen Y, Chen X, He Z, Zhu X, Hao Y (2017) Enterovirus 71 neutralizing antibodies seroepidemiological research among children in Guangzhou, China between 2014 and 2015: a cross-sectional study. Int J Environ Res Public Health 14(3). https://doi.org/10.3390/ijerph14030319
- Zhu R, Cheng T, Yin Z, Liu D, Xu L, Li Y, Wang W, Liu J, Que Y, Ye X, Tang Q, Zhao Q, Ge S, He S, Xia N (2018a) Serological survey of neutralizing antibodies to eight major enteroviruses among healthy population. Emerg Microbes Infect 7(1):2. https://doi.org/10.1038/s41426-017-0003-z CrossRefGoogle Scholar
- Zhu R, Xu L, Zheng Q, Cui Y, Li S, He M, Yin Z, Liu D, Li S, Li Z, Chen Z, Yu H, Que Y, Liu C, Kong Z, Zhang J, Baker TS, Yan X, Hong Zhou Z, Cheng T, Xia N (2018b) Discovery and structural characterization of a therapeutic antibody against coxsackievirus A10. Sci Adv 4(9):eaat7459. https://doi.org/10.1126/sciadv.aat7459 CrossRefGoogle Scholar